(Q33607742)

28 July 2017

title

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus (English)

1 reference

28 July 2017

1 reference

Takashi Kadowaki

1

1 reference

28 July 2017

Kazuoki Kondo

series ordinal

2

1 reference

28 July 2017

publication date

27 May 2013

1 reference

Journal of Diabetes Investigation

28 July 2017

published in

1 reference

28 July 2017

volume

4

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

576-584

1 reference

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020253

beta-cell failure in diabetes and preservation by clinical treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020253

Pioglitazone: a review of Japanese clinical studies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020253

Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020253

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020253

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020253

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020253

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 June 2018

1 reference

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Pioglitazone: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

21 January 2018

1 reference

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

21 January 2018

1 reference

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24843712

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/JDI.12092

1 reference

28 July 2017

1 reference

28 July 2017

1 reference